4-Bromo-2,5-dimethoxyamphetamine

Identification

Name
4-Bromo-2,5-dimethoxyamphetamine
Accession Number
DB01484
Type
Small Molecule
Groups
Experimental, Illicit
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
32156-26-6
Weight
Average: 274.154
Monoisotopic: 273.036441408
Chemical Formula
C11H16BrNO2
InChI Key
FXMWUTGUCAKGQL-UHFFFAOYSA-N
InChI
InChI=1S/C11H16BrNO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3
IUPAC Name
1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine
SMILES
COC1=CC(Br)=C(OC)C=C1CC(C)N

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
AcepromazineAcepromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Acrivastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Acrivastine.Approved
Alcaftadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Alcaftadine.Approved
Alfentanil4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Alfentanil.Approved, Illicit
Alimemazine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmasilateAlmasilate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved, Experimental
AloglutamolAloglutamol may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental
Alphacetylmethadol4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
Alphaprodine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Alphaprodine.Illicit
AluminiumAluminium may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Ammonium chlorideThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmoxapineAmoxapine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
AmperozideAmperozide may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Amphetamine.Approved, Illicit
Antazoline4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Astemizole4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AzaperoneAzaperone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational, Vet Approved
Azatadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Azatadine.Approved
Azelastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Azelastine.Approved
Bamipine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Bamipine.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Benzatropine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Benzatropine.Approved
Bezitramide4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Brofaromine.Experimental
BromperidolBromperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Brompheniramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Brompheniramine.Approved
Buclizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Buclizine.Approved
Buprenorphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
Butorphanol4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Butyric Acid4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Butyric Acid.Experimental, Investigational
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Calcium silicateCalcium silicate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental
Carbinoxamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Carbinoxamine.Approved
Carfentanil4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Carfentanil.Illicit, Investigational, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
Cetirizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cetirizine.Approved
Chloropyramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Chloropyramine.Approved
Chlorphenamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Chlorphenamine.Approved
Chlorphenoxamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
ChlorpromazineChlorpromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational, Withdrawn
Cimetidine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cimetidine.Approved
Cinnarizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cinnarizine.Approved, Investigational
Clemastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Clemastine.Approved
ClomipramineClomipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
ClozapineClozapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Codeine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Cyclizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Cyproheptadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
DesipramineDesipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Desloratadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
Dexbrompheniramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dexbrompheniramine.Approved
Dexchlorpheniramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleate4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
Dextromoramide4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
Dextropropoxyphene4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
Dezocine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dezocine.Approved, Investigational
DibenzepinDibenzepin may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Dihydrocodeine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
Dihydroetorphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
Dihydromorphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
Dimenhydrinate4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dimenhydrinate.Approved
Dimetindene4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dimetindene.Approved, Investigational
Dimetotiazine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dimetotiazine.Approved
Diphenhydramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Diphenhydramine.Approved
Diphenoxylate4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
DosulepinDosulepin may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Doxepin4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Doxepin.Approved
Doxylamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPE4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of DPDPE.Experimental
DroperidolDroperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
Ebastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Emedastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Emedastine.Approved
Epinastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Epinastine.Approved, Investigational
Esmirtazapine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Esmirtazapine.Investigational
Ethopropazine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Withdrawn
Ethylmorphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
Etorphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
Famotidine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Illicit, Withdrawn
Fentanyl4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
Fexofenadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Fexofenadine.Approved
FluanisoneFluanisone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
Flunarizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational, Vet Approved
Glutamic AcidThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
HarmalineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Harmaline.Experimental
Heroin4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Heroin.Approved, Illicit, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
Hydrocodone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
Hydromorphone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Investigational
Hydroxyzine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
ImipramineImipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Ioflupane I-1234-Bromo-2,5-dimethoxyamphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
IproclozideIproclozide may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Isothipendyl4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Isothipendyl.Approved
Ketobemidone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Ketobemidone.Approved, Investigational
Ketotifen4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ketotifen.Approved
Lafutidine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Lafutidine.Investigational
Lavoltidine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Lavoltidine.Investigational
Levocabastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Levocabastine.Approved
Levocetirizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl Acetate4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved, Investigational
Levorphanol4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Levorphanol.Approved
LithiumLithium may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Lodoxamide4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Lodoxamide.Approved
Lofentanil4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
Loratadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
MagaldrateMagaldrate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
Meclizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
Meptazinol4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Meptazinol.Experimental
Mepyramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
Mequitazine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
Methadone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Methadone.Approved
Methadyl Acetate4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
Methapyrilene4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
MethenamineThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
Metiamide4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Metiamide.Experimental
Mianserin4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mianserin.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Mirtazapine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mirtazapine.Approved
Mizolastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
MolindoneMolindone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
MoperoneMoperone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
Morphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
Nalbuphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
Nicomorphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Nicomorphine.Experimental
Nizatidine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Nizatidine.Approved
Normethadone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
OctamoxinOctamoxin may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
Olopatadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
OpipramolOpipramol may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Opium4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Opium.Approved, Illicit
OsanetantOsanetant may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Oxatomide4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Oxatomide.Investigational
Oxycodone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
Oxymorphone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
Ozagrel4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
PargylinePargyline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Pemirolast4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Pemirolast.Approved, Investigational
PenfluridolPenfluridol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
Pentazocine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
PerospironePerospirone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Pethidine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Pethidine.Approved
Phenazocine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Phenindamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
Pheniramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Pheniramine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with 4-Bromo-2,5-dimethoxyamphetamine.Approved
Phenoperidine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
PipamperonePipamperone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
PipotiazinePipotiazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
Piritramide4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
ProcarbazineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Procarbazine.Approved
ProchlorperazineProchlorperazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
Promethazine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Quifenadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Quifenadine.Experimental
RacloprideRaclopride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Ranitidine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Remifentanil4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
RisperidoneRisperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Roxatidine acetate4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Roxatidine acetate.Approved, Investigational
SafrazineSafrazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational, Withdrawn
Sodium bicarbonateSodium bicarbonate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Sufentanil4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
SultoprideSultopride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
Tapentadol4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Tapentadol.Approved
Terfenadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Terfenadine.Withdrawn
Tesmilifene4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
ThiopropazateThiopropazate may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
ThioridazineThioridazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Thonzylamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
TiaprideTiapride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
Tilidine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Tilidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Tramadol4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Tramadol.Approved, Investigational
Tranilast4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
TrifluperidolTrifluperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Tripelennamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
Triprolidine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Triprolidine.Approved
Tritoqualine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Tritoqualine.Experimental
TromethamineTromethamine may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
VeraliprideVeralipride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
Vitamin CThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
ZotepineZotepine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
62065
PubChem Substance
46507989
ChemSpider
55902
BindingDB
50005257
ChEMBL
CHEMBL6607
IUPHAR
163
Guide to Pharmacology
GtP Drug Page

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.58HANSCH,C & LEO,AJ (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.0948 mg/mLALOGPS
logP2.53ALOGPS
logP2.26ChemAxon
logS-3.5ALOGPS
pKa (Strongest Basic)9.9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity64.25 m3·mol-1ChemAxon
Polarizability25.28 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9962
Blood Brain Barrier+0.9475
Caco-2 permeable+0.7137
P-glycoprotein substrateNon-substrate0.711
P-glycoprotein inhibitor INon-inhibitor0.804
P-glycoprotein inhibitor IINon-inhibitor0.9441
Renal organic cation transporterNon-inhibitor0.8015
CYP450 2C9 substrateNon-substrate0.8693
CYP450 2D6 substrateSubstrate0.6261
CYP450 3A4 substrateSubstrate0.5248
CYP450 1A2 substrateInhibitor0.8743
CYP450 2C9 inhibitorNon-inhibitor0.8389
CYP450 2D6 inhibitorInhibitor0.8451
CYP450 2C19 inhibitorNon-inhibitor0.7714
CYP450 3A4 inhibitorNon-inhibitor0.7737
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.5865
CarcinogenicityNon-carcinogens0.7668
BiodegradationNot ready biodegradable0.9808
Rat acute toxicity3.0047 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8956
hERG inhibition (predictor II)Non-inhibitor0.617
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Bromobenzenes / Aralkylamines / Alkyl aryl ethers / Aryl bromides / Organopnictogen compounds / Organobromides
show 2 more
Substituents
Amphetamine or derivatives / P-dimethoxybenzene / Dimethoxybenzene / Phenylpropane / Phenoxy compound / Anisole / Methoxybenzene / Phenol ether / Alkyl aryl ether / Bromobenzene
show 17 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on July 31, 2007 07:09 / Updated on December 01, 2017 14:43